Nader Rita, El Amm Joelle, Aragon-Ching Jeanny B
Department of Internal Medicine, Lebanese American University, Beirut 1102 2801, Lebanon.
Department of Internal Medicine, Division of Hematology and Oncology, Lebanese American University, Beirut 1102 2801, Lebanon.
Asian J Androl. 2018 May-Jun;20(3):221-229. doi: 10.4103/aja.aja_40_17.
Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found to be largely palliative in nature and hardly resulted in durable or meaningful responses, docetaxel resulted in the first chemotherapy agent that showed improvement in overall survival in metastatic castration-resistant prostate cancer (mCRPC). However, combination chemotherapy or any agents added to docetaxel have failed to yield incremental benefits. The improvement in overall survival as well as secondary endpoints of prostate-specific antigen (PSA) and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. There are also promising results in locally advanced PCa and high-risk PCa in both the neoadjuvant and adjuvant settings. This review summarizes the historical as well as the more contemporary use of chemotherapeutic agents in PCa in varying states and phases of disease.
前列腺癌（PCa）的化疗经历了巨大的格局变化。早期研究采用了不同的化疗方案，这些方案在很大程度上被发现具有姑息性质，几乎没有产生持久或有意义的反应，而多西他赛成为首个在转移性去势抵抗性前列腺癌（mCRPC）中显示出总生存期改善的化疗药物。然而，联合化疗或添加到多西他赛中的任何药物都未能带来额外益处。在转移性激素敏感状态下使用多西他赛时，总生存期以及前列腺特异性抗原（PSA）和复发时间等次要终点的改善改变了新诊断的初发转移性PCa的治疗标准。在局部晚期PCa和高危PCa的新辅助和辅助治疗中也取得了令人鼓舞的结果。本综述总结了化疗药物在PCa不同疾病状态和阶段的历史及现代应用情况。
